Introduction: Transplant surgeons conventionally select against livers displaying high
| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a wide spectrum of nonalcohol-related, fatty liver disorders, which range from bland steatosis (NAFL, non-alcoholic fatty liver) to severe non-alcoholic steatohepatitis (NASH). 1 NAFL is characterized by hepatocyte steatosis and is considered a benign condition. In contrast, NASH is characterized by hepatocyte damage and inflammation, and has the potential to progress to advanced fibrosis and cirrhosis. 2 NAFLD is associated with obesity, diabetes, dyslipidemia, and metabolic syndrome. Almost all patients with NAFLD are insulin-resistant, and it is believed that NAFLD is the hepatic manifestation of insulin resistance. 3, 4 The obesity epidemic and the increasing concomitant prevalence of both metabolic syndrome and insulin resistance have resulted in increasing rates of NAFLD worldwide. 5 Studies indicate that the prevalence of NAFLD in the adult US population is 30%-40%, and it is estimated that 15%-20% of those NAFLD patients have NASH. 6 As a result, millions of patients are at risk of their liver disease progressing to cirrhosis and potentially requiring liver transplantation (LT). 7, 8 In fact, NAFLD is expected to become the leading indication for LT within the next 10-20 years. 1 The increased prevalence of NAFLD in the population also affects the quality and quantity of donor livers available for LT. 9 Currently, more than 15 000 patients are waiting for LT, but only 6000 liver transplants are performed annually across the United States. As a result, about 1500 patients a year die waiting for a liver, making the mortality on the liver transplant waiting list between 5% and 10% per year. 10 In response to the shortage of donor livers, transplant centers have increasingly attempted to maximize the supply of livers, by utilizing extended criteria and high-risk donors.
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Donor hepatic steatosis is one of the many factors believed to be related to increased risk. 19 Here, we report our finding that donor steatosis resolves following transplantation and discuss some of the clinical considerations in using such livers for transplant. 
| MATERIALS AND METHODS

| Study population
| Donor data
| Histological examination
Donor biopsy samples used in this study were generally both core needle and wedge liver biopsy samples obtained at the time of procurement. Postoperative recipient biopsies were either percutaneous or transjugular. Steatosis was categorized into MaS, characterized by one large fat droplet displacing the nucleus to the cytoplasmic border, and MiS, characterized by multiple small vacuoles surrounding a central nucleus. 19 
Percent MaS or MiS indicates the percent of MaS or
MiS involvement in the specimen. The donor biopsies were reported by the local pathologist, whereas all postoperative biopsies were reported by a single pathologist at our institution.
| Statistical analysis
All missing data for each variable were noted. Continuous data are presented as median (range) or mean±standard deviation (SD 
| RESULTS
| Donor and recipient demographics
Demographics of the 29 donors are presented in Table 1 . There was a statistically significant inverse relationship between donor age and donor MiS in our sample (P=.003). There was no significant relationship between donor BMI and either donor MaS or MiS. Demographics of the 29 recipients who received postoperative biopsies are presented in Table 2 . There were statistically significant inverse relationships between recipient age and MELD (P=.049), and also between recipient age and peak AST following LT (P=.045).
| Biopsy data
The breakdown of steatosis on preoperative biopsy is shown in 
| Survival data
The 30-day survival and 1-year survival of all 47 patients receiving liver transplants with greater than 15% MaS or MiS were stratified by those who did or did not undergo postoperative biopsies, as shown in Table 4 .
| Operative variables and complications
Operative characteristics are included in 
| Postoperative interventions and complications
Postoperative interventions and complications for the primary study group of 29 patients are included in 15, 21, 22 In addition to the initial resolution, we also observed that there was no evidence of recurrent steatosis in the longer term biopsies, which may relate to the fact that none of the recipients in the study group originally had NASH.
| DISCUSSION
The recipient biopsies were obtained at a median of 68 days postoperative (range 4-384 days). Biopsies were taken for cause, and not at standardized intervals, which accounts for the wide range and precludes the ability to accurately comment on the length of time for steatosis to resolve, although it appears to generally occur within the first 3 months following transplantation.
In our study, there was no statistical relationship between any recipient, donor, or operative characteristics with either the absolute resolution of steatosis or the time to resolution of steatosis.
Notably, donor steatosis resolves in patients irrespective of their MELD at transplant and their indication for transplant. While none of the recipients in the primary study group were formally diagnosed with NASH cirrhosis, this was not by design, as we do not intentionally avoid using steatotic grafts for recipients with NASH; moreover, given the high prevalence of hypertension (62.1%) and diabetes (37.9%), it is possible that some of the patients had at least a component of NASH, although it was not the diagnosed primary cause of their liver disease. This theory may lead to the conclusion that intraoperative and/or postoperative factors are responsible for the subsequent resolution of steatosis. These factors are currently unknown but may be iatrogenic, immunologic, metabolic, or genetic, among other possible explanations. The near universal resolution of fat is a very encouraging finding and supports the notion that steatosis is highly reversible with robust mechanisms for therapeutic targets.
Investigations into the mechanisms responsible for this phenomenon have been initiated. 23 In an in vitro model, for example, Nativ et al. 24 have demonstrated the effect of hypoxia/reoxygenation on lipid droplets in hepatocytes, as a representation of the ischemia/ reperfusion process in transplantation. A potential treatment to reverse obesity-related disease, such as NAFLD, may also be applicable to medical fields outside of liver transplantation and could have a substantial effect on public health.
We were surprised to find that there was no significant relationship between donor BMI and either donor MaS or MiS. This suggests that potential donors with even markedly elevated BMI should not be prematurely disregarded on the presumption of severe hepatic steatosis. Conversely, procuring surgeons must be prepared to encounter donors with regular BMI yet substantial steatosis.
One-year patient survival (92.9%) for all recipients of fatty livers in our study was superior to the nationwide average reported by Scientific Registry of Transplant Recipients (88.8%), or our center's outcomes for all LT. 10 Such favorable outcomes may be due, at least in part, to the fact that the average MELD for the study recipients (22.9) was lower than our overall average, which reflects an intentional selection practice, as we generally try to avoid using such grafts for the highest MELD recipients. When our survival data are stratified into the groups with and without postoperative biopsies, 1-year survival was 88.5% and 100%, respectively. Patients received postoperative biopsies for cause; thus, it is reasonable that the individuals who were biopsied were experiencing complications and/or graft injury, and therefore had inferior survival. 28 Steatosis is known to decrease the liver's ability to cope with ischemia/reperfusion injury, which may suggest that steatosis can predispose grafts to biliary stricture. 29 Baccarani et al. 30 reported that correlation directly, identifying graft MaS as an independent risk factor for biliary complications.
T A B L E 5 Perioperative variables
Our study supports that notion and further suggests that donor graft steatosis is correlated with postoperative biliary stricture. In addition, in our study, 1-year survival for patients with biliary stricture was 75%, which was inferior to both the national average for LTs and the average within our study. As the utilization of extended criteria donor continues, steatosis must be recognized as a risk factor for biliary strictures, which in turn may be associated with inferior patient outcomes.
Three patients who underwent ERCP were found to have a normal radiographic appearance of the biliary system. The established pathophysiology regarding bilirubin and the utilization of steatotic grafts may play a role in this outcome. Following ischemia, bilirubin levels tend to lag behind AST/ALT, being slower to both increase and decrease. Steatosis accentuates this lag in bilirubin, which may unnecessarily prompt ERCP. Awareness of this lag in bilirubin may help to possibly avoid unnecessary procedures.
In total, 44.8% of patients required reoperation within 90 days.
Ninety-day reoperation rate following LT has been reported in the literature as 29.3%. 31 In our study, it is very important to differentiate between the indications for reoperation. The single most common indication for reoperation in our study was planned delayed closure for size mismatch, which permitted edema to decrease and for the liver mass to shrink before closing the abdominal wall. Many of the steatotic livers are procured from higher BMI donors, and are overall larger in size, and although we generally consider the size matching of the donor and recipient, we prioritize additional variables in the selection process. Only one patient required planned closure for pack removal following coagulopathy, demonstrating that organ dysfunction was only a minor cause of reoperation. Importantly, 1-year survival was 100% for patients who underwent planned delayed closure,
showing the safety and efficacy of this approach. As the utilization of large steatotic grafts increases, it is important to be prepared for a substantial size discrepancy and recognize that planned delayed closure is a favorable surgical solution with excellent patient outcomes.
We acknowledge several limitations to this study, most importantly that it is retrospective and with a relatively small sample size.
The donor biopsies were reported by a local pathologist, and we no longer have the slides to be able to have them reviewed by a single experienced pathologist. Postoperative biopsies were performed only for cause, and so the timing and performance of such biopsies are inconsistent. Additionally, longer follow-up may be valuable. Nonetheless, we believe that our initial experience has been insightful, and we plan to build on this experience, as we work collaboratively toward a more optimal utilization of steatotic grafts.
| CONCLUSION
High degrees of MaS, MiS, and total steatosis in donor livers resolve in recipients following LT. Future investigations are necessary to identify the mechanisms responsible for the marked resolution of hepatic steatosis following transplantation. Insight into the mechanisms responsible for the resolution of donor NAFLD following LT could lead to therapeutic targets for treating NAFLD. In addition, our study demonstrates that carefully selected and managed steatotic donor grafts can be safely used in LT, particularly when CIT is minimized; however, an elevated incidence of postoperative complications should be expected, primarily biliary strictures and planned delayed closure for size mismatch. And ultimately, in the setting of a major organ shortage, the degree of acceptable steatosis should be reconsidered in donor selection.
